49 Wealth Management LLC Boosts Position in AbbVie Inc. $ABBV

Key Points

• 49 Wealth Management increased its AbbVie stake by 70.6% in the second quarter, bringing its holdings to 10,846 shares worth approximately $2.73 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie reported strong growth prospects, including positive Phase 3 results for etentamig, the $10.9 billion Apogee Therapeutics acquisition, and continued sales growth from Skyrizi and Rinvoq. However, Humira’s ongoing biosimilar-related decline remains a major headwind.
• Analysts maintain a broadly positive view, with AbbVie receiving a “Moderate Buy” consensus rating and an average price target of $275.95. The company also exceeded quarterly earnings and revenue expectations and reaffirmed its 2026 earnings guidance.

49 Wealth Management LLC raised its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 70.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,846 shares of the company's stock after buying an additional 4,487 shares during the period. AbbVie comprises 0.3% of 49 Wealth Management LLC's holdings, making the stock its 26th biggest holding. 49 Wealth Management LLC's holdings in AbbVie were worth $2,729,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in the stock. Litman Gregory Wealth Management LLC bought a new stake in AbbVie during the 4th quarter valued at $28,000. Imprint Wealth LLC grew its position in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after buying an additional 45 shares in the last quarter. Burk Holdings LLC purchased a new position in shares of AbbVie during the second quarter valued at $30,000. Legacy Wealth Managment LLC ID increased its stake in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock valued at $31,000 after buying an additional 73 shares during the period. Finally, IFC & Insurance Marketing Inc. bought a new stake in shares of AbbVie in the fourth quarter valued at about $31,000. 70.23% of the stock is currently owned by institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers a major Phase 3 win: AbbVie said its investigational BCMA x CD3 therapy met both primary endpoints in the CERVINO trial for relapsed/refractory multiple myeloma. Etentamig produced a 74% objective response rate versus 45.7% for standard therapies and reduced the risk of disease progression or death by 60%. The results could support a regulatory submission and give AbbVie an opportunity to compete in the growing BCMA-targeted treatment market. AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial
• Positive Sentiment: Apogee acquisition expands immunology pipeline: AbbVie completed its approximately $10.9 billion purchase of Apogee Therapeutics. The deal adds late-stage zumilokibart for atopic dermatitis and additional respiratory and inflammatory disease programs, potentially strengthening growth beyond Humira. AbbVie Completes Acquisition of Apogee Therapeutics
• Positive Sentiment: Growth products continue to offset Humira erosion: Skyrizi and Rinvoq remain key drivers, with reported second-quarter sales growth of 24% and 25%, respectively. AbbVie’s established dividend record and broader pipeline also support the long-term investment case.
• Neutral Sentiment: Financial guidance was reaffirmed: AbbVie maintained its 2026 adjusted EPS outlook of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88. However, the Apogee transaction is expected to dilute earnings initially before becoming accretive later in the decade. AbbVie Completes Acquisition of Apogee Therapeutics
• Negative Sentiment: Humira remains a significant headwind: The flagship drug’s revenue continues to fall following biosimilar competition, raising questions about how quickly newer products can replace the lost cash flow and support future dividend growth.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Barclays increased their target price on shares of AbbVie from $275.00 to $300.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. Morgan Stanley reaffirmed an "overweight" rating and issued a $296.00 price target on shares of AbbVie in a research report on Monday, August 3rd. Weiss Ratings raised shares of AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a report on Tuesday, August 4th. HSBC reissued a "buy" rating and issued a $300.00 price objective on shares of AbbVie in a research note on Monday, July 6th. Finally, Evercore set a $235.00 target price on AbbVie in a research report on Friday, May 15th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and an average price target of $275.95.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company's stock.

AbbVie Stock Down 0.1%

Shares of AbbVie stock opened at $256.27 on Monday. The firm's 50 day moving average price is $254.66 and its 200-day moving average price is $230.05. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $267.47. The company has a market cap of $452.78 billion, a P/E ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same quarter in the prior year, the company posted $2.97 earnings per share. AbbVie's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie's payout ratio is presently 195.48%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.